Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
0.100 Biomarker disease BEFREE Pharmacological inhibition of the MEK5/ERK5 and PI3K/Akt signaling pathways synergistically reduces viability in triple-negative breast cancer. 31464004 2020
Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
0.100 Biomarker disease BEFREE Thus, Torin2 and its chemical analogs represent a mechanistically distinct class of PI3K pathway inhibitors that are uniquely cytotoxic to TNBC cells. 31812693 2020
Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
0.100 AlteredExpression disease BEFREE The AKT inhibitor capivasertib has shown preclinical activity in TNBC models, and drug sensitivity has been associated with activation of PI3K or AKT and/or deletions of PTEN. 31841354 2020
Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
0.100 Biomarker disease BEFREE Novel therapeutic avenues in triple-negative breast cancer: PI3K/AKT inhibition, androgen receptor blockade, and beyond. 31636720 2019
Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
0.100 Biomarker disease BEFREE <b>Conclusion:</b> We demonstrated that DFO could upregulate expression of TfR1 and DMT1 , which enhanced iron uptake via activating IL-6/PI3K/AKT signaling pathway in aggressive TNBCs. 31213851 2019
Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
0.100 Biomarker disease BEFREE In the present study, we investigated whether miR-361-5p can act as a tumor suppressor by targeting required for cell differentiation 1 homolog (RQCD1) and inhibiting epidermal growth factor receptor (EGFR)/phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) pathway in TNBC. 29924958 2019
Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
0.100 Biomarker disease BEFREE TBCRC 032 IB/II Multicenter Study: Molecular insights to AR antagonist and PI3K inhibitor efficacy in patients with AR+ metastatic triple-negative breast cancer. 31822498 2019
Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
0.100 Biomarker disease BEFREE This study provides a preclinical rationale to investigate the therapeutic potential for the combination of PI3K inhibition and eribulin in the difficult to treat TNBC. 31217901 2019
Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
0.100 AlteredExpression disease BEFREE The disease-free survival and overall survival were significantly better in TNBC with PIK3CA protein expression, independent of TNBC subtypes. 31270600 2019
Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
0.100 GeneticVariation disease BEFREE The mutational profile of TNBC during treatment as inferred from patterns of mutant allele frequencies in matched pre-and post-NAC samples showed that RD harbored alterations of cell cycle progression, PI3K/Akt/mTOR, and EGFR tyrosine kinase inhibitor-resistance pathways. 31717320 2019
Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
0.100 Biomarker disease BEFREE This review will focus on recent therapeutic innovations for TNBC, including poly-ADP-ribosyl polymerase (PARP) inhibitors, phosphoinositide 3-kinase (PI3K) pathway inhibitors, immune checkpoint inhibitors, and cyclin-dependent kinase (CDK) inhibitors. 31254268 2019
Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
0.100 Biomarker disease BEFREE This review discusses the potentials and drug discovery perspectives of PI3K/AKT/mTOR as a therapeutic target for effective management of TNBC with anticipated challenges. 31520748 2019
Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
0.100 Biomarker disease BEFREE Consequently, targeted therapies based on the interaction of PI3K inhibition with BRCA1 mutations or HR deficiency in TNBC may be a promising strategy for the treatment of patients with TNBC. 31804921 2019
Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
0.100 Biomarker disease BEFREE In this study, we investigated a strategy to improve efficacy of PI3K-α inhibitor BYL719 (alpelisib) in TNBC. 31101835 2019
Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
0.100 Biomarker disease BEFREE Mechanistically, DCC-2036 targeted AXL/MET, especially AXL, and regulated the downstream PI3K/Akt-NFκB signaling to exert its antitumor effect in TNBC. 30289981 2019
Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
0.100 Biomarker disease BEFREE The present study examined the effects of tetrandrine suppressing proliferation, targeting LC3, p62, and Beclin-1 autophagy genes by inhibiting PI3K/AKT/mTOR signaling in Triple-negative breast cancer (TNBC) MDA-MB-231 cell. 30713576 2019
Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
0.100 Biomarker disease BEFREE In this study, we compared the effect of eribulin on the PI3K/AKT/mTOR pathway with other microtubule-targeting agents in TNBC. 31480338 2019
Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
0.100 Biomarker disease BEFREE Alteration of the PI3K/AKT/mTOR pathway is a common genomic abnormality detected in triple-negative breast cancer (TNBC). 31703728 2019
Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
0.100 Biomarker disease BEFREE We review the evidence for PI3K pathway activation in TNBC, and clinical trial data for PI3K, AKT and mammalian target of rapamycin inhibitors in TNBC. 31050709 2019
Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
0.100 Biomarker disease BEFREE The question of whether any of these mutated genes (e.g., PIK3CA) may represent a useful therapeutic target in TNBC may be answered by ongoing clinical trials and/or larger dataset analysis. 29589138 2018
Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
0.100 Biomarker disease BEFREE Our study suggests that the combination of WES and RNA-seq on human TNBC will lead to the identification of actionable therapeutic targets for precision medicine-guided TNBC treatment.<b>Significance:</b> Using combined WES and RNA-seq analyses, we identified sporadic oncogenic events in TNBC mouse models that share the capacity to activate the MAPK and/or PI3K pathways. 29203461 2018
Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
0.100 Biomarker disease BEFREE Here, we provide new evidence of the effects of exercise on TNBC prevention, control, and outcomes, based on the inhibition of the phosphatidylinositol-3-kinase (PI3K)/protein kinase B (PKB also known as Akt)/mammalian target of rapamycin (mTOR) (PI3K-Akt-mTOR) signaling. 30363988 2018
Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
0.100 GeneticVariation disease BEFREE CF33 was effective <i>in vitro</i> with potent cytotoxicity and efficient intracellular replication observed in TNBC lines with phosphatidylinositol 3-kinase (PI3K)/Akt pathway mutations that resulted in endogenous phospho-Akt (p-Akt) activity (BT549, Hs578T, and MDA-MB-468). 29988465 2018
Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
0.100 GeneticVariation disease BEFREE Notably, homozygous deletion of PTEN (n = 6) or activating mutation in PIK3CA (n = 1) was not associated with increased expression of either immune checkpoint activator in TNBC. 29996881 2018
Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
0.100 Biomarker disease BEFREE Further study of underlying mechanisms demonstrated that DANCR bound with RXRA and increased its serine 49/78 phosphorylation via GSK3β, resulting in activating PIK3CA transcription, and subsequently enhanced PI3K/AKT signaling and TNBC tumorigenesis. 30518934 2018